Alkermes Plc (ALKS) - Total Liabilities

Latest as of March 2026: $2.51 Billion USD

Based on the latest financial reports, Alkermes Plc (ALKS) has total liabilities worth $2.51 Billion USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Alkermes Plc - Total Liabilities Trend (1991–2025)

This chart illustrates how Alkermes Plc's total liabilities have evolved over time, based on quarterly financial data. See Alkermes Plc working capital to net assets to evaluate short-term liquidity relative to the company's equity base.

Alkermes Plc Competitors by Total Liabilities

The table below lists competitors of Alkermes Plc ranked by their total liabilities.

Company Country Total Liabilities
Indutrade AB
ST:INDT
Sweden Skr17.06 Billion
Beijing Kunlun Tech Co Ltd
SHE:300418
China CN¥5.29 Billion
The Swatch Group AG
SW:UHR
Switzerland CHF1.72 Billion
S-Oil Corp
KO:010950
Korea ₩17.67 Trillion
Figma, Inc.
NYSE:FIG
USA $837.57 Million
Merlin Properties SOCIMI SA
MC:MRL
Spain €5.99 Billion
Pearson plc
F:PESA
Germany €2.79 Billion
Wisetech Global Ltd
AU:WTC
Australia AU$4.67 Billion

Liability Composition Analysis (1991–2025)

This chart breaks down Alkermes Plc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Alkermes Plc worth.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 2.27 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 1.43 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.59 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Alkermes Plc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Alkermes Plc (1991–2025)

The table below shows the annual total liabilities of Alkermes Plc from 1991 to 2025.

Year Total Liabilities Change
2025-12-31 $710.96 Million +20.38%
2024-12-31 $590.59 Million -36.74%
2023-12-31 $933.54 Million +1.45%
2022-12-31 $920.23 Million +0.91%
2021-12-31 $911.90 Million +3.30%
2020-12-31 $882.75 Million +22.61%
2019-12-31 $719.96 Million +10.13%
2018-12-31 $653.72 Million +9.98%
2017-12-31 $594.42 Million +14.99%
2016-12-31 $516.94 Million -4.53%
2015-12-31 $541.47 Million +3.25%
2014-12-31 $524.43 Million +2.35%
2013-12-31 $512.40 Million -1.07%
2012-12-31 $517.92 Million -10.91%
2011-12-31 $581.37 Million +862.05%
2010-12-31 $60.43 Million -41.32%
2009-12-31 $102.98 Million +2.29%
2008-12-31 $100.67 Million -71.32%
2007-12-31 $351.00 Million +1.49%
2006-12-31 $345.84 Million -6.82%
2005-12-31 $371.14 Million +10.87%
2004-12-31 $334.76 Million +82.96%
2003-12-31 $182.97 Million -7.52%
2002-12-31 $197.85 Million -15.01%
2001-12-31 $232.78 Million -12.22%
2000-12-31 $265.18 Million +9.47%
1999-12-31 $242.25 Million +382.59%
1998-12-31 $50.20 Million -6.75%
1997-12-31 $53.83 Million +110.72%
1996-12-31 $25.55 Million +5.91%
1995-12-31 $24.12 Million +55.62%
1994-12-31 $15.50 Million +7.64%
1993-12-31 $14.40 Million +128.57%
1992-12-31 $6.30 Million +320.00%
1991-12-31 $1.50 Million --

About Alkermes Plc

NASDAQ:ALKS USA Drug Manufacturers - Specialty & Generic
Market Cap
$8.81 Billion
Market Cap Rank
#2785 Global
#976 in USA
Share Price
$52.83
Change (1 day)
+4.72%
52-Week Range
$26.13 - $52.83
All Time High
$80.14
About

Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and … Read more